Hospital
Commonspirit Oregon
Commonspirit Oregon was paid $13.70M by Medicaid between Jan 2018 and Dec 2024, across 65 billing codes. Its largest line is 99284, emergency room visit (serious) — 41% of everything it billed.
33Billing provider infoCOMMONSPIRIT OREGON
PENDLETON, OR 97801
PENDLETON, OR 97801
33aNPI1649276734assigned 06/22/2005
33bProvider typeCritical Access Hospital
28Total paid$13.70M
24GClaims126,628
24DCodes billed65
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Oregon
Rank by total paid#6 of 22
Median peer was paid$3.52M
This provider vs. median3.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,330 | $1.12M | |
| 2019 | 13,090 | $1.49M | |
| 2020 | 12,272 | $1.31M | |
| 2021 | 16,380 | $1.83M | |
| 2022 | 25,047 | $2.51M | |
| 2023 | 25,799 | $2.86M | |
| 2024incomplete | 21,710 | $2.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 41% | 11,447 | 9,902 | $5.62M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 14,916 | 13,311 | $3.62M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 3,445 | 2,789 | $1.98M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.1% | 7,193 | 6,166 | $429K |
| 71045 | Radiologic examination, chest; single view | 2.5% | 3,280 | 2,701 | $338K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.0% | 3,543 | 3,012 | $269K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 3,065 | 2,491 | $216K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.0% | 4,292 | 3,018 | $142K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 750 | 696 | $118K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,477 | 2,181 | $108K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,889 | 480 | $95K |
| 80053 | Comprehensive metabolic panel | <1% | 15,385 | 12,838 | $88K |
53 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 17,117 | $68K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,170 | $46K |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 1,592 | $44K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 99 | $44K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,285 | $43K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 836 | $43K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 536 | $41K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 720 | $38K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,790 | $33K |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,725 | $26K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 850 | $23K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 14 | $20K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 453 | $19K |
| 95811 | <1% | 36 | $16K | |
| 59025 | Fetal non-stress test | <1% | 103 | $15K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 212 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 212 | $13K |
| 81001 | <1% | 7,912 | $13K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 766 | $11K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 395 | $10K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 84 | $10K |
| J2704 | Injection, propofol, 10 mg | <1% | 406 | $8K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 42 | $7K |
| 84484 | <1% | 1,125 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 91 | $6K |
| 76801 | <1% | 25 | $6K | |
| 84703 | <1% | 1,103 | $6K | |
| 83690 | <1% | 1,363 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 289 | $4K |
| 83735 | <1% | 1,120 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 12 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 232 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 64 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 205 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 93 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 189 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 110 | $2K |
| 83880 | <1% | 70 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 61 | $1K |
| 81003 | <1% | 730 | $675.88 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 35 | $638.56 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 32 | $508.80 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 61 | $458.33 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 135 | $442.58 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 16 | $355.21 |
| A9270 | Non-covered item or service | <1% | 232 | $261.53 |
| 85610 | <1% | 96 | $227.51 | |
| 99406 | <1% | 17 | $212.55 | |
| 80305 | <1% | 27 | $148.20 | |
| 85379 | <1% | 15 | $103.55 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 16 | $36.27 |
| 85730 | <1% | 15 | $29.22 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPOINDEXTER, JAMIE (MARKET VP OPERATIONAL FINANCE)
Parent organizationCOMMONSPIRIT HEALTH
| Provider | Location | Paid |
|---|---|---|
| Commonspirit Oregon | Roseburg, OR | $29.19M |
| Commonspirit Oregon | Pendleton, OR | $277K |
| Commonspirit Oregon | Roseburg, OR | $128K |
| Commonspirit Oregon | Roseburg, OR | $92K |
| Commonspirit Oregon | Pendleton, OR | $72K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.